一心为民 全心服务 关于使用部分暂时闲置自有资金进行现金管理到期收回的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 一、现金管理到期收回情况 根据 2024 年年度股东会决议，公司与相关银行签署合同，使用部分暂时闲置自有资金进 行现金管理，现部分产品到期收回，基本情况如下： | 签约银行 | 产品名称 | 认购金额 | 收益类型 | 合同起始日 | 合同到期日 | 收益（元） | | --- | --- | --- | --- ...

Core Insights - YXTT (002727.SZ) reported its Q3 2025 results, revealing that 21 institutional investors hold a total of 105 million shares, representing 17.96% of the company's total equity [1] - The top ten institutional investors collectively own 16.48% of YXTT, with a decrease of 1.04 percentage points compared to the previous quarter [1] Institutional Holdings - In the public fund sector, seven funds increased their holdings, including Rongtong Health Industry Flexible Allocation Mixed A/B and Rongtong New Growth Mixed A, with an increase rate of 1.17% [2] - Six public funds reduced their holdings, including Guotai Ruiyin Rui Li Mixed (LOF) A, with a decrease rate of 0.15% [2] - Six new public funds were disclosed this period, including Xingquan Trend Investment Mixed (LOF) and Xingquan He Tai Mixed A [2] - A total of 153 public funds were not disclosed this period, including GF Technology Innovation Mixed A and GF Value Core Mixed A [2] Foreign Investment - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings, with an increase rate of 0.64% [2]

Core Viewpoint - The company has announced its financial results for the third quarter of 2025, including a plan for asset impairment provisions and a cash dividend distribution to shareholders [14][24]. Financial Data - The company reported a tax-prepared profit reduction of RMB 11.47 million due to asset impairment provisions for the first three quarters of 2025 [14][19]. - The company also reported a tax-prepared profit reduction of RMB 15.68 million due to credit impairment losses for the same period [16][19]. - The cash dividend distribution plan involves a payout of RMB 2 per 10 shares, totaling RMB 114.83 million (including tax) [5][6]. Business Development - The company is focusing on expanding its traditional Chinese medicine business, particularly in the areas of food and medicine integration, formula granules, and national standard products [7]. - The first centralized healthcare center has achieved breakeven within two years, and a second center is under construction, expected to open in the first half of 2026 [8]. - The company has revamped 805 stores in its non-pharmaceutical business segment, which includes health foods, medical devices, and wellness products, contributing significantly to overall performance growth [10].

Core Viewpoint - YXTT (002727.SZ) reported a decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating revenue of 13.001 billion yuan, a year-on-year decrease of 4.33% [1] - The net profit attributable to shareholders was 269 million yuan, down 8.17% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 253 million yuan, reflecting a significant decline of 26.27% year-on-year [1]

Core Insights - YXTT reported a decline in both revenue and net profit for the first three quarters of 2025 [1] Financial Performance - YXTT's revenue for the first three quarters reached 13.001 billion yuan, representing a year-on-year decrease of 4.33% [1] - The net profit attributable to shareholders was 269 million yuan, down 8.17% year-on-year [1]

Core Viewpoint - YXTT is a well-known pharmaceutical retail chain in China, with a strong brand influence and mature supply chain system, primarily engaged in pharmaceutical retail and wholesale business [1] Financial Performance - In Q3 2025, YXTT reported revenue of 13.001 billion, ranking 4th among 8 companies in the industry, with the industry leader DSR's revenue at 20.068 billion and the average at 10.731 billion [2] - The net profit for the same period was 280 million, also ranking 4th, with the industry leader YF's net profit at 1.321 billion and the average at 478 million [2] Financial Ratios - As of Q3 2025, YXTT's debt-to-asset ratio was 52.85%, lower than the previous year's 54.06% and the industry average of 61.53%, indicating good solvency [3] - The gross profit margin for Q3 2025 was 32.46%, up from 31.73% year-on-year and above the industry average of 31.47%, showing improved profitability [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 10.53% to 37,500, while the average number of shares held per shareholder decreased by 9.53% to 10,600 [5] - Notable changes among the top ten shareholders include an increase in holdings by Hong Kong Central Clearing Limited and other funds [5] Business Strategy and Outlook - YXTT is facing pressure on performance due to a slight decrease in the number of stores, but is actively improving store formats and introducing new product categories [6] - The company aims to enhance service quality and strengthen new retail business, with new retail sales reaching 730 million in H1 2025, a year-on-year increase of 13.6% [6] - Analysts have adjusted earnings forecasts for 2025-2027, with target prices set at 17.00 and 18.47, maintaining a "buy" rating [6]

一心堂药业集团股份有限公司 第六届董事会 2025 年第七次独立董事专门会议审核意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》等法律、行政法规、中国证券监督管理委员会行政规章和规范性文件、深 圳证券交易所相关规则及规定以及《一心堂药业集团股份有限公司章程》等有关规 定，一心堂药业集团股份有限公司（以下简称"公司"）独立董事于 2025 年 10 月 27 日召开了第六届董事会 2025 年第七次独立董事专门会议。独立董事本着实事求 是、认真负责的态度，公平、公正、诚实信用的原则，基于独立判断的立场，对公 司第六届董事会第十八次会议相关事项进行了认真审核，并发表审核意见如下： 一、关于 2025 年前三季度计提资产减值准备的议案 杨先明 龙小海 陈旭东 一心堂药业集团股份有限公司 2025 年 10 月 27 日 独立董事签名： 经审查，公司本次计提资产减值准备遵循了《企业会计准则》要求的谨慎性原 则，能够更加公允反映公司的财务状况和经营成果，有助于提供真实、可靠、准确 的会计信息，不存在损害公司 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-110 号 一心堂药业集团股份有限公司 关于 2025 年前三季度计提信用减值及资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年10月30日召开第六届董事会第 十八次会议，审议通过《关于2025年前三季度计提资产减值准备的议案》，根据相关规定，现 将具体情况公告如下： 一、本次计提减值准备情况概述 （一）本次计提减值准备的原因 根据《企业会计准则》《深圳证券交易所股票上市规则》及公司《财务管理制度》的相关 规定，为客观、公允、准确的反映公司截至2025年9月30日的财务状况、资产价值和2025年前三 季度的经营成果，公司对合并报表范围内截至2025年9月30日的各类资产进行了全面清查和充分 的评估分析，判断部分资产存在减值的迹象，需要计提减值准备。 （二）本次计提减值准备的资产范围和金额 公司进行清查和资产减值测试后，对部分资产计提资产减值准备，使得本年1-9月税前利润 减少人民币1,147.19万元。 ...

一心为民 全心服务 表决结果：同意 9 票，反对 0 票，弃权 0 票。 一心堂药业集团股份有限公司 第六届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 一心堂药业集团股份有限公司(以下简称"公司")第六届董事会第十八次会议于2025年10 月30日10时以现场及通讯表决方式在公司会议室召开，本次会议于2025年10月17日通过邮件及 书面形式发出通知。本次会议应出席会议的董事为9人，实际出席会议的董事为9人。公司非董 事高级管理人员列席了会议。本次会议的召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。会议由阮鸿献先生主持。与会董事逐项审议了有关议案并做出决议 如下。 二、董事会会议审议情况 1、审议通过《关于公司 2025 年第三季度报告的议案》 《2025 年第三季度报告》详见公司指定信息披露媒体《证券时报》《中国证券报》《证券 日报》和巨潮资讯网（www.cninfo.com.cn）。并批准 2025 年第三季度财务报告对外报出。 股票代码：002727 股票简称：一心堂 公告 ...

Financial Performance - The company's revenue for Q3 2025 was ¥4,086,535,700.64, representing a decrease of 4.62% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥18,941,635.48, an increase of 78.71% year-on-year, while net profit excluding non-recurring items was ¥9,935,344.15, down 78.04%[5]. - The company reported a basic earnings per share of ¥0.0324, an increase of 82.02% year-on-year[5]. - Total operating revenue for the current period is CNY 13,001,028,971.88, a decrease of 4.3% from CNY 13,589,430,513.51 in the previous period[26]. - Net profit for the current period is CNY 279,953,869.97, a decline of 8.7% compared to CNY 306,673,555.30 in the previous period[27]. - Earnings per share (EPS) for the current period is CNY 0.4587, down from CNY 0.4908 in the previous period[27]. Assets and Liabilities - The total assets at the end of the reporting period were ¥15,841,053,806.65, a decrease of 5.88% from the end of the previous year[5]. - The company's total assets decreased from 16,830,316,478.61 CNY to 15,841,053,806.65 CNY[24]. - The total liabilities decreased from 7,631,183,301.72 CNY to 6,979,005,378.72 CNY[24]. - Total liabilities amount to CNY 8,371,468,517.29, a decrease from CNY 9,177,027,604.21[25]. - Total equity attributable to shareholders of the parent company is CNY 7,317,083,552.48, down from CNY 7,491,014,022.79[25]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥1,432,091,712.35, reflecting a growth of 15.42%[5]. - Operating cash inflow for the current period was CNY 12,704,003,248.60, a decrease of 3.49% from CNY 13,165,397,205.14 in the previous period[28]. - Net cash flow from operating activities increased to CNY 1,432,091,712.35, up 15.43% from CNY 1,240,746,217.23 year-on-year[28]. - Cash inflow from investment activities totaled CNY 2,467,651,564.49, significantly higher than CNY 221,281,983.49 in the previous period[28]. - Cash inflow from financing activities was CNY 580,060,000.00, an increase from CNY 457,060,000.00 in the previous period[29]. - Net cash flow from financing activities was negative at CNY -1,139,973,371.69, an improvement from CNY -1,309,261,172.78 year-on-year[29]. Investments and Expenditures - The company increased its investment in other equity instruments by 272.86%, totaling ¥13,050,000.00, due to new investments and adjustments in existing holdings[9]. - The construction in progress increased by 210.73% to ¥111,198,725.40, driven by multiple ongoing projects including digital manufacturing bases[10]. - Cash paid for operating activities was CNY 11,271,911,536.25, a decrease from CNY 11,924,650,987.91 in the previous period[28]. - Total cash outflow for investment activities was CNY 2,417,100,285.50, compared to CNY 599,520,771.70 in the previous period[28]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,494[15]. - The largest shareholder, 阮鸿献, holds 31.12% of the shares, amounting to 182,245,290 shares[15]. - The company approved a cash dividend of 2 CNY per 10 shares, totaling 114,825,645 CNY (including tax) for the 2025 interim profit distribution[18]. Business Segments and Operations - The traditional Chinese medicine segment focuses on developing innovative products in the food and medicine integration field, enhancing product standardization and convenience[19]. - The first centralized healthcare center achieved breakeven within two years, with a second center under construction expected to open in the first half of 2026[20]. - The non-pharmaceutical business segment has completed the upgrade of 805 stores, with significant growth driven by the health and wellness category, maintaining high double-digit growth in the first three quarters of 2025[21].